Slide 1: Pfizer Forms Global Alliance with Merck KGaA to Accelerate Presence in Immuno-Oncology
Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology November 17, 2014
Slide 2: Forward-looking statements
Forward-looking statements Our discussions during this conference call will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2013 Annual
Slide 3: Pfizer and Merck KGaA: A Great Match
Pfizer and Merck KGaA, Darmstadt, Germany: A Great Match • Strong global commitment to Oncology development and commercialization • Investing heavily in Together, one team immuno-oncology R&D Focused on committed to driving rapid improving the and broad development lives of patients and commercializ
Slide 4: Key Deal Terms
Key Deal Terms • Upfront payment of $850 million to Merck KGaA, Darmstadt, Germany Co-Development and • Merck KGaA, Darmstadt, Germany is eligible to receive regulatory and commercial milestone payments up to approximately $2 billion Co-Commercialization • Pfizer and Merck KGaA, Darmstadt, Germany w
Slide 5: Collaboration Positions both Companies into Potential Wave 1 of Immunotherapy Launches
Collaboration Positions both Companies into Potential Wave 1 of Immunotherapy Launches Wave 1 Wave 2 Single Agent IO Combinations PD-L1/PD-1 Initiating up to 20 clinical development Provides backbone for Wave 2: programs, Potential single agent entry in key combinations with Pfizer’s extensive inclu
Slide 6: Current clinical program of Anti-PD-L1
Current clinical program of Anti-PD-L1 Anti-PD-L1 studies Large Phase I, open-label trial to Signal finder Expansion investigate the safety, pharmacokinetics studies (10mg/kg IV 2q week) cohorts and clinical activity in patients with solid tumors n = 20* n = 150* Expansion to selected indication
Slide 7: Phase I efficacy result: Response rates in NSCLC
Phase I efficacy result: Response rates in NSCLC Time to and duration of response Best Overall Response NSCLC by RECIST 1.1 Intent-to-treat, 1020004 unconfirmed n = 90 (%) 1220003 Complete Response (CR) 1 (1.1%) 1550002 1220009 Individual patients Partial Response (PR) 11 (12.2%) 1020023 1020025 Sta
Slide 8: Phase I results in ovarian cancer: Tumor shrinkage and duration of response
Phase I results in ovarian cancer: Tumor shrinkage and duration of response Patients with ovarian cancer (n = 21*) 120 Best Overall Response by RECIST 1.1 Ovarian cancer unconfirmed n = 23; n (%) Change in target lesions from baseline 100 80 First occurrence of new lesion 60 Complete Response (CR) 0
Slide 9: Phase I safety results: Adverse Events
Phase I safety results: Adverse Events Current safety information based on an analysis of Pooled expansion 290 subjects (expansion NSCLC Ovarian cancer part of study -001) cohorts (n = 127) (n = 23) (n = 290) Cut-off date: July 16, n (%) n (%) n (%) 2014 Minimum follow-up time: 4 weeks AEs 262
Slide 10: Pfizer's Existing Immuno-oncology Portfolio is Complemented by Merck KGaA's Anti-PD-L1
Pfizer’s Existing Immuno-oncology Portfolio is Complemented by Merck KGaA’s, Darmstadt, Germany Anti-PD-L1 Pfizer and Merck, KGaA, Darmstadt, Germany Pfizer’s Immuno-Oncology Portfolio Collaboration Killing of cancer cells De-bulk tumor and Reduce Immune Promote Immune release cancer antigens Suppre
Slide 11: Collaboration Will Leverage Pfizer's Broad Oncology Pipeline
Collaboration Will Leverage Pfizer’s Broad Oncology Pipeline Pfizer Oncology Pipeline Potential combination Pfizer and opportunities within Pfizer’s Merck KGaA, oncology pipeline include: Darmstadt, Germany Anti-PD-L1 • Small molecules • Antibodies and ADCs • Vaccines Pipeline provides opportunities
Slide 12: Q&A
Q&A 12